Editorial board

EDITORIAL BOARD

EDITOR-IN-CHIEF

Dr. Luis G. Valerio Jr, U.S. Food and Drug Administration (FDA), Washington, DC, USA

Luis G. Valerio, Jr., Ph.D., is currently an Associate Director at the U.S. Food and Drug Administration (FDA). Dr. Valerio has a strong background in public health and is multi-faceted having served with increasing responsibilities at the FDA Center for Drug Evaluation and Research, Center for Food Safety and Applied Nutrition, and the Center for Tobacco Products; contributing in areas of review, risk/safety science, compliance and enforcement, and applied regulatory research. For over 10 years he has made significant contributions to the field of computational toxicology, providing foundations and creating pioneering in silico predictive models for expert decision-support. Prior to joining the FDA, he was Head of Toxicology and Translational Science at Verto Solutions, LLC, in Washington, DC. Of notable significance, he was Scientific Director of the Flavor and Extract Manufacturers Association (FEMA) of the United States. At FEMA he ensured the safety of flavors for the industry. He has also been an industrial consumer product safety toxicologist for several years. He received his Ph.D. in Pharmaceutical Science (1998) from the University of Colorado, and was a Gastroenterology Fellow at the University of Colorado School of Medicine where he focused on hepatic metabolism of xenobiotics and molecular mechanisms of toxicity. He was a U.S. National Science Foundation International Research Postdoctoral Fellow at the Autonomous University of Barcelona, Spain where he studied the biochemistry of the alcohol dehydrogenase enzyme family. He received his Bachelor of Arts in Environmental, Population, and Organismic Biology from the University of Colorado, at Boulder. Valerio is internationally recognized and has strong experience in emerging and predictive technologies in toxicology, pharmacokinetics, regulatory toxicology, and in pharmaceutical product science. His research interests include predictive metabolism, computational modeling, and development of strategies and methods for risk analysis. He has been on the advisory board of Expert Opinion on Drug Metabolism and Toxicology since 2009 and has been Editor-in-Chief since 2011.

Editorial Board Members

Prof. Karel Allegaert, KU Leuven, Leuven, Belgium

Prof. Mark Cronin, Liverpool John Moores University, Liverpool, UK

Prof. Jose De Leon, University of Kentucky, Lexington, KY, USA

Prof. Amílcar Falcão, University of Coimbra, Coimbra, Portugal

Prof. Simone Ferrero, University of Genoa, Genoa, Italy

Prof. Gert Fricker, University of Heidelberg, Heidelberg, Germany

Prof. Slobodan Jankovic, University of Kragujevac, Kragujevac, Serbia

Prof. Jeffrey Lipman, University of Queensland, Brisbane, Australia

Dr. Geert Mannens, Janssen Pharmaceuticals, Beerse, Belgium

Prof. Olavi Pelkonen, University of Oulu, Oulu, Finland

Dr. Mario Pellegatti, Retired GSK Director, Verona, Italy

Prof. Godefridus J Peters, VU University Medical Center, Amsterdam, Netherlands

Dr. Italo Poggesi, Certara, Lombardia, Italy

Dr. Adrian Ray, Gilead Sciences Inc., Foster City, CA, USA

Prof. Jim Riviere, Kansas State University, Manhattan, KS, USA

Prof. André Scheen, University of Liège, Liège, Belgium

Prof. Nicolas Simon, Aix-Marseille Université, Marseille, France

Prof. Edoardo Spina, University of Messina, Messina, Italy

Prof. Yoshiya Tanaka, University of Occupational & Environmental Health Japan, Kitakyushu, Japan

Prof. Rolf Teschke, Klinikum Hanau, Hanau, Germany

Prof. Brian Tomlinson, Chinese University of Hong Kong, Hong Kong SAR

Prof. Jack Uetrecht, University of Toronto, Toronto, ON, Canada

Prof. Vasilis Vasiliou, Yale University, New Haven, CT, USA

Prof. Thomas J Walsh, Cornell University, Ithaca, NY, USA

Dr. Hong Wan, WHDeX Consulting AB, Mölndal, Sweden

Prof. Baojian Wu, Jinan University, Guangzhou, China